Introduction
Post-myocardial infarction (MI) patients often present with frequent premature ventricular complexes (PVCs) and nonsustained ventricular tachycardia (VT). These arrhythmias are not only symptomatic but also serve as markers for increased mortality and sudden cardiac death. Historically, the management of ventricular ectopy has relied on conventional antiarrhythmic drugs that target cardiac ion channels (Class I and Class III agents). However, evidence from landmark trials like the CAST study has shown that many of these agents, while effective at suppressing ectopy, carry a significant risk of proarrhythmia and can increase mortality in the post-MI population.
This has led to a clinical demand for alternative therapeutic approaches. Recent research has identified cardiac nicotinic acetylcholine receptors (nAChRs) as a novel electrophysiological target. Varenicline, well-known as a partial nAChR agonist used for smoking cessation, has shown potential in modulating cardiac excitability. This report details the findings of a phase 2 trial investigating varenicline’s efficacy and safety in reducing ventricular ectopy after MI.
Patient Information and Methodology
The study, titled the Var-PVC trial, was a multicenter, randomized, double-blind, placebo-controlled phase 2 study. The cohort consisted of 118 adults who had suffered a myocardial infarction at least four weeks prior to enrollment.
Inclusion Criteria:
– Adults (age ≥18).
– History of MI at least 4 weeks prior.
– Frequent PVCs, defined as ≥1,000 per 24 hours.
– Stable guideline-directed medical therapy (GDMT).
Exclusion Criteria:
– Malignant ventricular arrhythmias requiring an ICD.
– Significant renal or hepatic impairment.
– Current use of nicotine replacement therapy or other antiarrhythmic drugs (except beta-blockers).
Participants were monitored using 72-hour ambulatory electrocardiographic (ECG) monitoring to establish a baseline. They were then randomly assigned in a 1:1 ratio to receive either varenicline 0.5 mg twice daily or a matching placebo for a duration of 45 days.
Diagnosis and Assessment
The diagnosis of frequent PVCs was confirmed via the 72-hour Holter monitoring. At baseline, both groups exhibited a high burden of ventricular ectopy. The primary focus of the assessment was the percentage change in the 24-hour PVC count from the baseline to the 6-week follow-up. Secondary assessments included the responder rate (defined as a ≥50% reduction in PVC burden) and the incidence of nonsustained VT.
Treatment and Management
All patients remained on their background guideline-directed medical therapy, which typically included beta-blockers, ACE inhibitors/ARBs, and antiplatelet agents. The intervention group received varenicline tartrate at a dose of 0.5 mg BID. This dosage is lower than the typical dose used for smoking cessation (which often titrates up to 1 mg BID), aimed at balancing efficacy with the specific safety profile needed for post-MI patients.
Monitoring during the 45-day period included regular clinical visits and a repeat 72-hour ambulatory ECG at week 6 to evaluate the primary and secondary endpoints.
Outcome and Prognosis
The results of the trial demonstrated a significant therapeutic benefit for patients receiving varenicline compared to the placebo group.
Primary Endpoint:
Varenicline produced a 60.1 percentage point greater reduction in PVC burden compared with the placebo group (95% CI: 21.3-98.8; P = 0.001). This represents a substantial clinical reduction in ectopy.
Secondary Endpoints:
– Responder Rate: 67.8% of patients in the varenicline group achieved a ≥50% reduction in PVCs, compared to only 30.5% in the placebo group (RR: 2.22; P < 0.0001).
– Nonsustained VT: The incidence of nonsustained VT was significantly lower in the varenicline group (20.3%) compared to the placebo group (37.3%) (RR: 0.49; P = 0.007).
Safety Profile:
There were no recorded deaths or malignant ventricular arrhythmias (such as sustained VT or ventricular fibrillation) in the varenicline group. Adverse event rates were comparable between the two groups, suggesting that varenicline was well-tolerated in this high-risk cardiovascular population.
Discussion
The Var-PVC trial provides significant proof-of-concept for the use of nAChR agonists in cardiac electrophysiology. The findings are particularly important given the limitations of current antiarrhythmic options for post-MI patients.
Significance of the Target:
Traditional antiarrhythmics target sodium, potassium, or calcium channels. While effective at altering conduction velocity or refractoriness, they often interfere with the global electrical stability of the heart. By targeting cardiac nicotinic acetylcholine receptors, varenicline modulates the autonomic influence and local excitability of the myocardium through a different pathway, potentially avoiding the proarrhythmic triggers associated with ion channel blockade.
Clinical Implications:
The reduction in both PVC burden and nonsustained VT is clinically relevant. High PVC burden is associated with the development of PVC-induced cardiomyopathy and increased risk of more severe arrhythmias. The ability to suppress these triggers safely in the post-MI setting—without the “rebound” or proarrhythmic risks seen with older drugs—represents a potential shift in management strategy.
Future Directions:
As a phase 2 study, the Var-PVC trial was focused on biological target engagement and short-term safety. While the results are promising, larger phase 3 trials are required to determine if this reduction in ventricular ectopy translates into improved long-term outcomes, such as a reduction in sudden cardiac death or improved left ventricular function. Furthermore, the optimal dosing and the long-term safety profile in patients with varying degrees of heart failure remain to be elucidated.
References
1. Shen Y, Guo X, Zeng C, et al. Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study. Journal of the American College of Cardiology. 2026; (Published online ahead of print). PMID: 41778949.
2. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial (CAST). N Engl J Med. 1991;324(12):781-788.
3. Wang DW, et al. Nicotinic Acetylcholine Receptors in the Heart: New Targets for Arrhythmia Management. Trends in Cardiovascular Medicine. 2024.
